ACE and kidney disorder: Preventing development and progression of kidney disease requires tight blood pressure control and, due to the important role of the RAAS in the pathogenesis of kidney disease, agents that inhibit this system (angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)) are recognized first-line therapy [3, 35, 36], both effectively lowering blood pressure and directly acting on the kidney.